NCT03782259 Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2 Status COMPLETED Phase PHASE4
NCT03762850 A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03710460 Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity Status UNKNOWN Phase PHASE4
NCT03619213 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. Status COMPLETED Phase PHASE3
NCT03592667 Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension Status UNKNOWN Phase PHASE4
NCT03499704 A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy Status COMPLETED Phase PHASE4
NCT03492580 A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease Status COMPLETED Phase N/A
NCT03387683 A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients Status COMPLETED Phase PHASE4
NCT03364985 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers Status COMPLETED Phase PHASE1
NCT03344341 A Phase IV Study in Drug-Naive Patients With T2DM in China Status TERMINATED Phase PHASE4
NCT03338855 Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles. Status COMPLETED Phase PHASE4
NCT03331289 Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria Status COMPLETED Phase PHASE4
NCT03316131 A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA Status COMPLETED Phase PHASE2
NCT03269058 Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes Status COMPLETED Phase PHASE4
NCT03249506 Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM) Status COMPLETED Phase N/A